AzTrials
AzTrials

Intermittent FastingNCT05558423

ZOE Health Study: The Intermittent Fasting Study

A study testing Time Restricted Eating in people with Intermittent Fasting and Time Restricted Feeding, run by Zoe Global Limited at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The timing of food intake (chrononutrition) is emerging as a key regulator of circadian rhythm in metabolic organs. A wealth of research has been conducted on intermittent fasting, and time restricted eating (TRE) specifically, investigating the temporal patterns of diet (eating window, time of eating, time of largest… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Intermittent Fasting, Time Restricted Feeding
What is being tested?
Time Restricted Eating
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150,000 participants
Where
1 siteUnited Kingdom
Study dates
24 Oct 2022to 24 Oct 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adults of 18 years and above, where the app has been approved for download from the Apple App and Google Play stores.

Who cannot join

  • Unable to provide written informed consent

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site, 1 recruiting
  • ZOE Limited

    London, SE1 7RW

    Christina Hu, 07950 335916, zoehealthstudy@kcl.ac.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: The Intermittent Fasting ZOE Health Study: Effects on Hunger, Mood, Energy and Symptom Burden in a UK Cohort

The timing of food intake (chrononutrition) is emerging as a key regulator of circadian rhythm in metabolic organs. A wealth of research has been conducted on intermittent fasting, and time restricted eating (TRE) specifically, investigating the temporal patterns of diet (eating window, time of eating, time of largest energy intake) and their impact on disease risk, with overall beneficial impact on health. Studies have been conducted in a parallel or single arm design, while cross-over and the efficacy of TRE in ameliorating appetite and symptom burden within an individual remains unclear.

Read the detailed description

Time Restricted Eating (TRE; a type of intermittent fasting) is a dietary pattern based on the 24h day. Practicing individuals restrict their eating/feeding window to a certain number of hours, e.g. 4h, while the remaining hours in the day are non-feeding (fasting) time. The eating window is the duration of time from the start of the first meal to the end of the last meal in a 24 hr period. The eating window in a general population has previously been quantified at 12h (American cohort of n=15,000). It is important to note that TRE differs from other intermittent fasting protocols by (i) not specifying a change in dietary intake, such as requiring caloric restriction, but rather specifying the temporal pattern of intake; and (ii) requiring consistent daily eating windows over several days. TRE protocols can vary in the length of the eating window, as well as the anchoring of that window to the time of day, such that early vs. middle vs. late TRE regimens exist.

While the cardiometabolic benefits TRE are well established by human trials, other outcomes of dietary compliance remain unexplored and thus bring into question the sustainability of and adherence to TRE as a long-term dietary regimen. Perception of hunger, mood and energy, and self-elected timings of TRE eating windows while following the dietary pattern are not well understood. In particular, the relative differences in these outcomes between an habitual and a TRE eating pattern within the same individual must be determined in order to truly evaluate the acceptability of TRE on a per-individual basis.

The Intermittent Fasting Study, a sub-study of the ZOE Health Study (ZHS), will test the effects of habitual eating patterns vs. a TRE protocol on hunger, mood, energy and symptom burden in an adult UK cohort using the ZHS app.

Population:

This study is open to all participants currently enrolled in the ZHS study tracking physical and mental symptom burden on a daily basis. Participants will be invited to take part in the Intermittent Fasting Study and must provide their consent in order to participate.

Design:

The study will take place remotely using a n-of-1 design, consisting of two phases with a non-randomised cross-over. Firstly, the participant will complete a baseline phase of one week, where they follow their habitual eating pattern.

Secondly, for the second and third weeks of the study, the participant will be asked to follow a TRE regimen with an eating window of ≤10 hours. The exact duration of the eating window, its timing relative to time of day, and participant dietary intake, are decisions deliberately left to the participant for two reasons; (i) to enable the participant to choose exactly the right TRE protocol that is most acceptable to them and therefore most likely to be sustainable in the long-term; (ii) to understand the trends in acceptability and feasibility of TRE regimens across this UK cohort. The participant is given the option of continuing their TRE phase beyond the minimum two weeks.

During the two phases, participants are asked to log the following outcomes in the ZHS app, on a daily basis:

  • Hunger (using visual analogue scales, VAS)
  • Mood (using VAS)
  • Energy (using VAS)
  • Symptom burden (using VAS)
  • Body weight (optional)
  • Clock time of the start of their first eating event
  • Clock time of the end of their last eating event

Participants may also be asked to log their diet during their baseline phase and their TRE phase (optional) such that the temporal effect of changing between their habitual and chosen TRE regimens on dietary intake can be determined. They will also be asked to complete questionnaires, at the start and end of the study, about their eating habits, gastrointestinal health, lifestyle and demographic.

Outcome analysis may be stratified according to demographic and other exposure parameters such as early vs. late TRE.

Being tested
Time Restricted Eating
Keywords
Intermittent Fasting, Time Restricted Eating, Hunger, Mood, Energy
Medical subject headings
Intermittent Fasting

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Time Restricted EatingBehavioural

    Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.

Study groups in NCT05558423
Study groupRoleWhat they receive
Self-controlledExperimentaln-of-1 design. Participants complete a baseline habitual eating phase following by an intervention TRE phase.
Receives: Behavioral: Time Restricted Eating

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. TRE window clock time

    The chosen clock time for the TRE window (early, vs. middle, vs. late)

    Measured: 2 weeks

  2. Habitual eating window clock time

    The chosen clock time for the habitual eating window

    Measured: 1 weeks

  3. Hunger

    Hunger levels reported by visual analogue scale ("how hungry did you feel yesterday?"; 0-10; where 10 is the most hungry)

    Measured: 3 weeks (plus optional unlimited weeks)

  4. Mood

    Mood levels reported by visual analogue scale ("how was your mood yesterday?"; 0-10; where 10 is most positive)

    Measured: 3 weeks (plus optional unlimited weeks)

  5. Energy

    Energy levels reported by visual analogue scale ("how energetic did you feel yesterday?"; 0-10; where 10 is most energetic)

    Measured: 3 weeks (plus optional unlimited weeks)

  6. Symptom burden

    The self-reported symptom burden while completing both habitual and TRE phases

    Measured: 3 weeks (plus optional unlimited weeks)

Secondary outcomes (3)
  1. Body weight

    Self-reported in the study app (optional)

    Measured: 3 weeks (plus optional unlimited weeks)

  2. Gastrointestinal symptoms

    Gastrointestinal symptoms self-reported by questionnaire

    Measured: 3 weeks (plus optional unlimited weeks)

  3. Eating habits

    Eating habits self-reported by questionnaire, including number of main meals and snacks per day

    Measured: 3 weeks (plus optional unlimited weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Sep 2022
  2. Study start24 Oct 2022
  3. Primary completion24 Oct 2023 (estimated)
  4. Study completion24 Oct 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
150,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05558423
Sponsor's protocol ID
ZHS-IF
Status last verified
Sep 2022
First submitted
23 Sep 2022
Last updated
30 Nov 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Time Restricted Eating in people with Intermittent Fasting and Time Restricted Feeding, run by Zoe Global Limited at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Christina Hu (07950 335916, zoehealthstudy@kcl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

TRE window clock time (time frame: 2 weeks). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in